Deubiquitinating and inhibiting Hsp90 by USP40 mitigates lung injury
USP40 去泛素化和抑制 Hsp90 可减轻肺损伤
基本信息
- 批准号:10618145
- 负责人:
- 金额:$ 44.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AcetylationAcuteAcute Lung InjuryAlveolarAnimal ModelAntibioticsBacteriaBacterial Antibiotic ResistanceBacterial InfectionsBlood capillariesCellsDataDeubiquitinating EnzymeDeubiquitinationDevelopmentDockingEdemaEndothelial CellsEndotheliumEndotoxinsEnzymesExhibitsExtravasationFoundationsGenerationsHSP 90 inhibitionHeat-Shock Proteins 90HospitalsInflammatoryInflammatory ResponseKnockout MiceLeadLifeLipopolysaccharidesLungLysineMediatingMolecularMonoubiquitinationMorbidity - disease rateMusPathogenesisPathway interactionsPermeabilityPhasePhosphorylationPlayPneumoniaPost-Translational Protein ProcessingProcessProteinsRegulationRoleSchemeSepsisSeveritiesSiteStressSuperbugTherapeuticUbiquitinUbiquitinationattenuationcell typecytokine release syndromeendothelial dysfunctioninhibitorlung injurylung preservationmortalitymouse modelneutrophilnovel therapeutic interventionnovel therapeuticspreservationprotein foldingprotein protein interactionresponserestraintside effectsmall molecule inhibitortherapeutic targetubiquitin isopeptidase
项目摘要
Abstract
Acute lung injury (ALI) is a life-threatening inflammatory lung condition that is most commonly
caused by pneumonia or sepsis. ALI-related mortality remains at unexpectedly high levels. Hence,
a new therapeutic strategy for ALI is needed. Uncontrolled cytokine storm, neutrophil influx into
alveolar spaces, and leakage from capillaries are the hallmarks of ALI, thus, a promising
therapeutic strategy in the acute phase of ALI is to restrain pro-inflammatory responses and
capillary barrier disruption simultaneously. Heat shock protein 90 (Hsp90) has been known to
contribute to the pathogenesis of ALI by promoting pro-inflammatory responses in a variety of
lung cell types and increasing endothelial cell (EC) permeability. Inhibition of Hsp90 activity by
small molecule inhibitors have been shown to reduce the severity of ALI in animal models
dramatically; however, molecular regulation of Hsp90 has not been well studied. We discovered
that Hsp90 can be mono-ubiquitinated and the mono-ubiquitination may compete with acetylation
of Hsp90 to increase Hsp90 activity. We identified that USP40, a DUB, deubiquitinates Hsp90,
thus resulting in inhibiting Hsp90. We hypothesize that deubiquitinating and inhibiting Hsp90 by
USP40 mitigate lung injury by suppressing pro-inflammatory responses and preserving EC barrier
integrity. We will determine the molecular mechanisms by which USP40 deubiquitinates and
inactivates Hsp90. Then, we will focus on determining the molecular mechanisms by which
USP40 mitigates pro-inflammatory responses and pulmonary EC barrier disruption through
deubiquitination of Hsp90. Lastly, we will determine if USP40 de-mono-ubiquitination of Hsp90
plays a protective role in murine models of ALI. These studies will be the first to elucidate the
protective role of inactivating Hsp90 by USP40 against lung injury.
摘要
急性肺损伤(ALI)是一种危及生命的炎症性肺部疾病,
是由肺炎或败血症引起的与ALI相关的死亡率仍然处于出乎意料的高水平。因此,我们认为,
需要一种新的治疗ALI的策略。不受控制的细胞因子风暴,中性粒细胞流入
肺泡腔和毛细血管渗漏是ALI的标志,因此,
急性期ALI的治疗策略是抑制促炎反应,
同时破坏毛细血管屏障。已知热休克蛋白90(Hsp90)
通过促进各种炎症反应,促进ALI的发病机制。
肺细胞类型和增加内皮细胞(EC)渗透性。Hsp90活性的抑制
在动物模型中,小分子抑制剂已显示出降低ALI的严重性
然而,Hsp90的分子调控尚未得到很好的研究。我们发现
Hsp90可以被单泛素化,并且单泛素化可能与乙酰化竞争
增加Hsp90的活性。我们发现USP 40(一种DUB)可以去遍在化Hsp90,
从而导致抑制Hsp90。我们假设,通过去泛素化和抑制Hsp90,
USP 40通过抑制促炎反应和保护EC屏障减轻肺损伤
完整我们将确定USP40去泛素化的分子机制,
使Hsp90失活。然后,我们将集中精力确定分子机制,
USP 40通过以下方式减轻促炎反应和肺EC屏障破坏
热休克蛋白90的去泛素化。最后,我们将确定USP40是否能使Hsp90去单泛素化
在ALI小鼠模型中起保护作用。这些研究将首次阐明
USP 40灭活Hsp90对肺损伤的保护作用。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Noncanonical HIPPO/MST Signaling via BUB3 and FOXO Drives Pulmonary Vascular Cell Growth and Survival.
- DOI:10.1161/circresaha.121.319100
- 发表时间:2022-03-04
- 期刊:
- 影响因子:20.1
- 作者:Kudryashova TV;Dabral S;Nayakanti S;Ray A;Goncharov DA;Avolio T;Shen Y;Rode A;Pena A;Jiang L;Lin D;Baust J;Bachman TN;Graumann J;Ruppert C;Guenther A;Schmoranzer M;Grobs Y;Eve Lemay S;Tremblay E;Breuils-Bonnet S;Boucherat O;Mora AL;DeLisser H;Zhao J;Zhao Y;Bonnet S;Seeger W;Pullamsetti SS;Goncharova EA
- 通讯作者:Goncharova EA
Non-Lethal Doses of RSL3 Impair Microvascular Endothelial Barrier through Degradation of Sphingosie-1-Phosphate Receptor 1 and Cytoskeletal Arrangement in A Ferroptosis-Independent Manner.
- DOI:10.3390/biomedicines11092451
- 发表时间:2023-09-04
- 期刊:
- 影响因子:4.7
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JING ZHAO其他文献
JING ZHAO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JING ZHAO', 18)}}的其他基金
Molecular regulation of immunoproteasome assembly in inflammatory diseases
炎症性疾病中免疫蛋白酶体组装的分子调控
- 批准号:
10637422 - 财政年份:2023
- 资助金额:
$ 44.37万 - 项目类别:
Deubiquitinating and inhibiting Hsp90 by USP40 mitigates lung injury
USP40 去泛素化和抑制 Hsp90 可减轻肺损伤
- 批准号:
10396562 - 财政年份:2020
- 资助金额:
$ 44.37万 - 项目类别:
Regulation of Histone Acetyltransferase Stability In Sepsis
脓毒症中组蛋白乙酰转移酶稳定性的调节
- 批准号:
9107899 - 财政年份:2015
- 资助金额:
$ 44.37万 - 项目类别:
Regulation of Histone Acetyltransferase Stability In Sepsis
脓毒症中组蛋白乙酰转移酶稳定性的调节
- 批准号:
8938959 - 财政年份:2015
- 资助金额:
$ 44.37万 - 项目类别:
Regulation of Histone Acetyltransferase Stability In Sepsis
脓毒症中组蛋白乙酰转移酶稳定性的调节
- 批准号:
9302464 - 财政年份:2015
- 资助金额:
$ 44.37万 - 项目类别:
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 44.37万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 44.37万 - 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
- 批准号:
10719249 - 财政年份:2023
- 资助金额:
$ 44.37万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 44.37万 - 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
- 批准号:
10741574 - 财政年份:2023
- 资助金额:
$ 44.37万 - 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
- 批准号:
23K07651 - 财政年份:2023
- 资助金额:
$ 44.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
- 批准号:
10679944 - 财政年份:2023
- 资助金额:
$ 44.37万 - 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
- 批准号:
10575258 - 财政年份:2023
- 资助金额:
$ 44.37万 - 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
- 批准号:
10701207 - 财政年份:2023
- 资助金额:
$ 44.37万 - 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
- 批准号:
10837431 - 财政年份:2023
- 资助金额:
$ 44.37万 - 项目类别: